The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/88812

Please be advised that this information was generated on 2017-04-08 and may be subject to change.
hypertensive drugs, such as calcium-channel blockers.\textsuperscript{1}

Rury R. Holman, M.B., Ch.B.
University of Oxford
Oxford, United Kingdom

Bjoern Holzhauer, Dipl.Math.
Novartis Pharma
Basel, Switzerland

John J. McMurray, M.B., Ch.B., M.D.
University of Glasgow
Glasgow, United Kingdom

Since publication of their article, the authors report no further potential conflict of interest.


Dutasteride and Prostate Cancer

\textbf{TO THE EDITOR:} In the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, Andriole et al. (April 1 issue)\textsuperscript{4} found that there was a reduction in low-grade prostate cancer among high-risk men after dutasteride treatment — similar to the results with finasteride therapy among low-risk men in the Prostate Cancer Prevention Trial.\textsuperscript{2} However, there was a slightly increased risk of high-grade tumors in the dutasteride group at the end of the study. The authors speculate that this was caused by the more frequent early detection of low-grade tumors in the placebo group. Some of these might have progressed to higher grades if left untreated. But if so, wouldn't this counterbalance the beneficial lower rate of biopsies for cause in the dutasteride group?

The end-of-study cumulative risk of prostate cancer among participants in the placebo group in both studies was extremely high (24 to 25%). With the use of data from the Surveillance, Epidemiology and End Results (SEER) program, one can calculate that participants in the Prostate Cancer Prevention Trial would have had a 7-year cumulative risk of only 6% if they had not participated in the trial. Participants in the REDUCE trial would have had a 4-year cumulative risk of 8 to 10% in the absence of protocol-driven biopsies, on the basis of data from the European Randomized Study of Screening for Prostate Cancer (Current Controlled Trials number, ISRCTN49127736).\textsuperscript{3} Thus, the protocol-directed interim and end-of-study biopsies make it impossible to directly translate the results to public health or clinical practice.

Lambertus A. Kiemeney, Ph.D.
Radboud University Nijmegen Medical Center
Nijmegen, the Netherlands
b.kiemeney@ebh.umcn.nl

Maarten C. Bosland, D.V.Sc., Ph.D.
University of Illinois at Chicago College of Medicine
Chicago, IL

No potential conflict of interest relevant to this letter was reported.


\textbf{TO THE EDITOR:} The long-expected results of the REDUCE trial show that among men 50 to 75 years of age who have prostate-specific antigen (PSA) levels of 2.5 to 10.0 ng per milliliter and who have previously undergone biopsies, the 5α-reductase inhibitor dutasteride significantly reduces the rate of positive biopsies by 23%. The 24.9% rate of positive biopsy results among men who underwent at least two biopsies is consistent with the expressed purpose of the organizers to study a population that had a relatively high risk of prostate cancer. Protocol-mandated biopsies were carried out at year 2 and year 4 during the study. This procedure is in line with clinical practice.

Unfortunately, the authors do not address the possibility of avoiding at least some of the 82.8% of negative biopsies. Although the difference in positive biopsies must be considered a very preliminary end point, the possibility that the use of dutasteride avoids unnecessary biopsies must be explored. It has great relevance in a clinical environment, in which the overdiagnosis and overtreatment of prostate cancer are considered to be a major health care problem.

Fritz H. Schröder, M.D.
Monique J. Roobol, Ph.D.
Erasmus Medical Center
Rotterdam, the Netherlands
secr.schroder@erasmusmc.nl
No potential conflict of interest relevant to this letter was reported.

TO THE EDITOR: In the editorial accompanying the article by Andriole et al., Walsh convincingly disproves the conclusion of the REDUCE study, stating that dutasteride does not prevent prostate cancer but merely shrinks tumors. According to Walsh, this holds true for finasteride as well. However, this view cannot provide a post hoc justification for the use of placebo instead of finasteride as a control in the trial of dutasteride therapy. The REDUCE trial was based on the alleged evidence that made finasteride the current standard of treatment—that is, the reported 25% reduction in the risk of prostate cancer and aimed at showing that dutasteride did as well and possibly better by avoiding the 27% increase with finasteride in less well differentiated tumors that are more likely to be lethal. These expectations were possibly fueled by the fact that, unlike finasteride, dutasteride inhibits both type 1 and type 2 5α-reductase.

How could all this have been proved without a comparison with finasteride? This comparison would have addressed the best interest of patients and national health services but might also have threatened the commercial prospects of finasteride, which its manufacturer hopes will replace the older but cheaper generic finasteride. Dutasteride, which its manufacturer hopes will have threatened the commercial prospects of finasteride, was at increased risk for prostate cancer but merely shrinks tumors. According to Walsh, this holds true for finasteride as well. However, this view cannot provide a post hoc justification for the use of placebo instead of finasteride as a control in the trial of dutasteride therapy. The REDUCE trial was based on the alleged evidence that made finasteride the current standard of treatment—that is, the reported 25% reduction in the risk of prostate cancer and aimed at showing that dutasteride did as well and possibly better by avoiding the 27% increase with finasteride in less well differentiated tumors that are more likely to be lethal. These expectations were possibly fueled by the fact that, unlike finasteride, dutasteride inhibits both type 1 and type 2 5α-reductase.

How could all this have been proved without a comparison with finasteride? This comparison would have addressed the best interest of patients and national health services but might also have threatened the commercial prospects of finasteride, which its manufacturer hopes will replace the older but cheaper generic finasteride.

Silvio Garattini, M.D.
Vittorio Bertele’, M.D.
Mario Negri Institute for Pharmacologic Research
Milan, Italy
silvio.garattini@marionegri.it

No potential conflict of interest relevant to this letter was reported.


TO THE EDITOR: Walsh dismisses the value of a reduction in moderately well-differentiated prostate tumors (tumors with a Gleason score of 5 or 6) in the REDUCE trial, suggesting that “many of the tumors were likely to have been clinically insignificant.” A diagnosis of cancer, even indolent cancer, is important for the patient. Cancers acquire major clinical significance if they drive radical intervention. And in the United States, 92% of patients who have prostate cancer with a favorable risk receive radical intervention with its attendant complications and effects on quality of life. Even patients who elect the approach of active surveillance acquire the “survivor” label and must deal with the psychological effects of a cancer diagnosis, repeated biopsies, and anxiety about the natural history of their cancer.

Modeling of data from the Prostate Cancer Prevention Trial has suggested that the rate of both high-grade and low-grade cancers is reduced by treatment with a 5α-reductase inhibitor. Whether one accepts this or not, the REDUCE study showed that dutasteride therapy, when used as a prevention strategy, will reduce overdiagnosis and hence overtreatment. This is of real value to patients.

Laurence Klotz, M.D.
University of Toronto
Toronto, ON, Canada
laurence.klotz@sunnybrook.ca

No potential conflict of interest relevant to this letter was reported.


THE AUTHORS REPLY: We agree with Kiemeney and Bosland that the results of the REDUCE trial cannot be directly translated to a clinical situation in which biopsies are performed only “for cause” and that the near elimination of high-grade tumors in the placebo group during years 3 and 4 may have been due to the fact that protocol-mandated biopsies were performed during years 1 and 2. Dutasteride may have inhibited the growth of low-grade and some high-grade tumors during years 1 and 2; hence, more remained to be detected during years 3 and 4. The rates of prostate cancer in the placebo group exceeded general estimates, as expected, since a population that was at increased risk for prostate cancer (on the basis of PSA levels) was selected for evaluation.

Schröder and Roobol ask whether dutasteride can help avoid biopsies among men who do not...
have prostate cancer. A large proportion of the negative biopsies in the REDUCE trial were protocol-mandated biopsies; in clinical practice, dutasteride should result in the need for fewer biopsies because it suppresses PSA production from benign tissue (and indolent prostate cancers), as seen in two previous studies.\(^1,2\) Data from the REDUCE trial showed that although rising PSA levels were a poor predictor of overall cancer and of high-grade cancer in the placebo group (perhaps since many placebo-treated men had rising PSA levels as a result of benign prostatic hyperplasia), rising PSA levels were a strong predictor of tumors with Gleason scores of 7 to 10 in the dutasteride group. The effect of dutasteride on the usefulness of PSA level for the diagnosis of prostate cancer would be the subject of a separate article.

Garattini and Bertele’ question why placebo (rather than finasteride) was chosen for comparison with dutasteride and whether the data from the REDUCE trial can help determine whether inhibition of both isoforms of 5α-reductase by dutasteride is superior to the inhibition of only one isoform by finasteride (as studied in the Prostate Cancer Prevention Trial). Finasteride was not used in the REDUCE trial for three main reasons: finasteride is not an approved therapy for reducing the risk of prostate cancer, the REDUCE trial was initiated before the results of the Prostate Cancer Prevention Trial were reported, and the reduction in the risk of prostate cancer with finasteride has never been tested in the population studied in the REDUCE trial (men with elevated PSA levels). Increased type 1 5α-reductase in prostate tumors, especially in high-grade tumors, provides a biologically based rationale for the use of a dual inhibitor of 5α-reductase to achieve a reduction in the risk of prostate cancer; however, the REDUCE trial was not designed to test this hypothesis directly. In a prespecified analysis of data from the REDUCE trial in which baseline predictors of prostate cancer and postbaseline prostate volume at the time of biopsy were incorporated into the model (see the Supplementary Appendix, available with the full text of the article at NEJM.org), the odds ratio for prostate cancer, detected on biopsy, with dutasteride as compared with placebo was 0.60 for all tumors (95% confidence interval [CI], 0.52 to 0.68; \(P<0.001\)) and 0.62 for tumors with Gleason scores of 7 to 10 (95% CI, 0.49 to 0.79; \(P=0.001\)).

The New England Journal of Medicine
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on December 6, 2012. For personal use only. No other uses without permission. Copyright © 2010 Massachusetts Medical Society. All rights reserved.

Gerald L. Andriole, M.D.
Washington University School of Medicine
St. Louis, MO
andrioleg@wustl.edu

Roger S. Rittmaster, M.D.
GlaxoSmithKline
Durham, NC

Since publication of their article, the authors report no further potential conflict of interest.

3. Thomas LN, Douglas RC, Lazier CB, et al. Levels of 5α-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008;179:14F-51.
Ultrasound-Guided Internal Jugular Vein Cannulation

TO THE EDITOR: We wish that Ortega et al. (April 22 issue) had demonstrated the use of the needle-guide technique in their video of internal jugular vein cannulation. As noted in the video, it can be difficult to determine the location of the tip of the needle, which may be either in front of or behind the narrow cross-sectional plane of the ultrasound image. With the use of a needle guide, the operator can direct the needle tip such that it intersects the middle of the image on the screen at the depth prescribed by the guide. This technique has been shown to be superior to the freehand technique in successfully cannulating the internal jugular vein.

We believe that the use of ultrasonography without a needle guide may give the operator a false sense of security, especially if the person doing the procedure lacks experience. Although imaging alone may help to identify the target vein, a needle guide allows for direct, real-time visualization of vessel puncture.

David Maslove, M.D.
Frederick Mihm, M.D.
Stanford University Medical Center
Stanford, CA
dmaslove@stanford.edu

No potential conflict of interest relevant to this letter was reported.


TO THE EDITOR: In their video, Ortega et al. failed to mention the use of the micropuncture technique for additional safety. A micropuncture needle is a very small, 22-gauge needle that can enter the jugular vein with little discomfort to the patient. Accidental puncture of the carotid artery with this small needle generally does not lead to major bleeding. The micropuncture technique is particularly helpful in children, in patients taking an anticoagulant, and in situations requiring immediate access. Unintentional penetration of the posterior wall of the internal jugular vein during placement of a central catheter occurs frequently, despite the use of ultrasound guidance. Use of the micropuncture needle can help to prevent the creation of a large posterior hole in the vein, thus reducing the likelihood of bleeding. In the cardiac catheterization laboratory at our institution, my colleagues and I recently switched to the exclusive use of the micropuncture technique to obtain any vascular access. We believe that use of this technique should become the standard of care in clinical practice.

Mohammad Reza Movahed, M.D., Ph.D.
Southern Arizona Veterans Affairs Health Care System
Tucson, AZ
rmova@aol.com

No potential conflict of interest relevant to this letter was reported.


THE AUTHORS REPLY: Despite the 18-minute duration of our video, the multitude of techniques and approaches that can be used for internal jugular vein cannulation made it necessary for us to carefully decide which points to include and